In this article published online and also in this issue, the authors wish to make a number of changes to the text under the section heading Reduced intensity conditioning regime and HCT procedure.
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The corrected text is as follows:
Reduced intensity conditioning regimen and HCT procedure The conditioning regimen for related HCT consisted of fludarabine (30 mg/m 2 /day for 5 days), thymoglobulin (2-5 mg/kg/day for 4-5 days, with i.v. continuous perfusion during 24 h), prednisone (2 mg/kg/day for 4-5 days) and melphalan (60 mg/m 2 /day on days À3 and À2). For patients undergoing unrelated HCT, melphalan (70 mg/ m 2 /day) was given on days À3 and À2, and cytarabine (2 g/m 2 /day, with i.v. continuous perfusion during 12 h) was also given on day À8. The patients received haematopoietic cell grafts from HLA-matched related or unrelated donors derived from either peripheral blood or BM on day 0. All patients received GVHD prophylaxis with CYA and mycophenolate mofetil. CYA was started on day À1 at 5 mg/kg twice daily and continued until 3-6 months, followed by tapering, if no GVHD was present. Trough levels of CsA were targeted at 180-380 ng/l. Mycophenolate mofetil was started and continued at 1 g twice daily until 1-3 months. GVHD treatment consisted of methylprednisolone and resumption of CsA, if already tapered. Infection prevention consisted of ciprofloxacin and fluconazol until granulocyte counts exceeded 500 cell/ml, and fluconazol was given for 3 months, unless GVHD was diagnosed, in which case fluconazol was continued for at least 6 months. Cotrimoxazol 960 mg on alternate days was given for 12 months, and acyclovir 500 mg/m 2 three times a day was given on the first 30 days. Then, it was continued at 200-800 mg twice daily for 6 months, unless GVHD was diagnosed, in which case acyclovir was continued for at least 12 months.
